Braingaze | ADHD & Autism Diagnosis and Therapy Solutions

What is Braingaze

Braingaze was originally founded as a spin-off company from the University of Barcelona in 2013, being now globally based with offices in both Barcelona, Spain and Surrey, UK. We provide BGaze Clinic, a reliable solution for the diagnosis, treatment and monitoring of cognitive disorders by using eye-movement and biomarker analysis techniques.

Our mission

Current diagnostic methods are often time-consuming, expensive and do not leverage the potential added value of digital tools. Braingaze aims to transform healthcare systems by integrating digital tools that offer a cost-effective, objective, and engaging patient journey.

The Experts Behind the Vision

A multidisciplinary team of scientists, engineers, and visionaries.

Laszlo Bax

Co-founder & CEO

Prof. Hans Supèr

Co-founder & CTO

Antonio Borrero

Lead Software Developer

Shihan Liu

Game Developer

Jordi Espada

Software Developer

Chamith Ranathunga

Lead AI Engineer

Hannah Lawton

Research and Clinical Officer

Nicolás Perea

Regulatory Lead

Deependra Dewagiri

Team Member

Braingaze Spain, Avinguda Ernest Lluch 32, Tecnocampus, 08302 Mataro (Barcelona) Spain

Braingaze UK, 157 High Street, New Malden (Greater London) KT3 4BH United Kingdom

Our Partners

Braingaze in the Media

Recent coverage and announcements from the field.

March 7th, 2024 by Charity Today.

"New innovative health technology fund aims to invest with impact"

A new health innovation fund is investing in health and care technologies and innovations to transform the current health and social care system, including improving access to and quality of care. The Special Opportunities Fund is starting with Braingaze, a revolutionary new tool that uses eye tracking to help diagnose ADHD in a matter of minutes. The tool enables drug-free cognitive disorders treatment and brings brain-related healthcare into the digital and AI-powered age.

May 18th, 2023 by Portaltic.

DTx Consortium and Vodafone Business will drive the adoption of digital therapies in Spain

The DTx Consortium and Vodafone Business will collaborate to promote the use of digital therapies in Spain. This agreement aims to promote access to innovative digital treatments to improve the health of the population. Vodafone Business will provide its infrastructure and technology to support the implementation and distribution of these therapies, thus facilitating their adoption nationwide.